Expression and Clinical Significance of MicroRNA-195 in Patients with Diffuse Large B Cell Lymphoma.
10.7534/j.issn.1009-2137.2020.01.027
- Author:
Rui-Dong LIU
1
;
Wei ZHUANG
1
;
Jiu-De QI
2
;
Chuan-Cui LI
3
Author Information
1. Department of Clinical Laboratorial Examination, Jinan People's Hospital, Jinan 271100, Shandong Province, China.
2. Department of Oncology, Jinan People's Hospital, Jinan 271100, Shandong Province, China,E-mail: sdlwqjd@163.com.
3. Department of Hematology, Jinan People's Hospital, Jinan 271100, Shandong Province, China.
- Publication Type:Journal Article
- From:
Journal of Experimental Hematology
2020;28(1):160-164
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the expression and clinical significance of microRNA-195 in patients with diffuse large B cell lymphoma(DLBCL).
METHODS:Sixty patients with DLBCL were selected from nearly four years in our hospital, and at the same time 30 healthy people with physical examination of the same period and with the same age in our hospital were choosed as control group. Real-time fluorescent quantitative PCR (RT-qPCR) was used to detect the miR-195 expression of the patients and controls, the relationship between miR-195 expression and clinicopathological characteristics of DLBCL and survival time of patients was analyzed.
RESULTS:The expression level of miR-195 in DLBCL patients was significantly lower than that in the controls (P<0.001). The expression level of miR-195 closely related with tumor diameter, IPI score and Ann Arbor stage of patients with DLBCL. Overall survival(OS) time of DLBCL patients with highly expressed miR-195 was significantly longer than that of patients with low expression (P<0.001).
CONCLUSION:miR-195 expression decrease in DLBCL patients, and miR-195 closely relates with tumor characteristics of patients with DLBCL. DLBCL patients with higher expression of miR-195 show longer overall survival time.
